Presenter Status

Fellow

Abstract Type

Research

Primary Mentor

Keith August, MD, MS

Start Date

16-5-2024 11:30 AM

End Date

16-5-2024 1:30 PM

Presentation Type

Poster Presentation

Description

BACKGROUND: Pegaspargase (SS-PEG) became unavailable to younger patients in 2022, leaving calaspargase pegol (SC-PEG) as the only available long-acting asparaginase formulation. SC-PEG has been compared to SS-PEG and found to have similar rates of adverse events and event-free survival. Our institution uses a desensitization protocol for those with asparaginase hypersensitivity reactions. Here we review our experience with desensitization since the transition to SC-PEG. OBJECTIVES: To compare the rate of hypersensitivity reactions, success of desensitization, and need for alternative asparaginase preparations between patients receiving SC-PEG and SS-PEG. METHOD: This is a retrospective, single center study of pediatric patients who received >2 doses of SC-PEG from November 2022 – December 2023. RESULTS: We report 26 patients with acute lymphoblastic leukemia and lymphoma who received >2 doses of SC-PEG. The frequency of a grade 2 or higher clinical hypersensitivity reaction was 42.3% (n=11). Silent inactivation, defined as serum asparaginase activity (SAA)

Share

COinS
 
May 16th, 11:30 AM May 16th, 1:30 PM

An Increased Failure Rate Of Asparaginase Desensitization With Calaspargase Pegol

BACKGROUND: Pegaspargase (SS-PEG) became unavailable to younger patients in 2022, leaving calaspargase pegol (SC-PEG) as the only available long-acting asparaginase formulation. SC-PEG has been compared to SS-PEG and found to have similar rates of adverse events and event-free survival. Our institution uses a desensitization protocol for those with asparaginase hypersensitivity reactions. Here we review our experience with desensitization since the transition to SC-PEG. OBJECTIVES: To compare the rate of hypersensitivity reactions, success of desensitization, and need for alternative asparaginase preparations between patients receiving SC-PEG and SS-PEG. METHOD: This is a retrospective, single center study of pediatric patients who received >2 doses of SC-PEG from November 2022 – December 2023. RESULTS: We report 26 patients with acute lymphoblastic leukemia and lymphoma who received >2 doses of SC-PEG. The frequency of a grade 2 or higher clinical hypersensitivity reaction was 42.3% (n=11). Silent inactivation, defined as serum asparaginase activity (SAA)